ProShare Advisors LLC boosted its stake in shares of Celgene Corporation (NASDAQ:CELG) by 10.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 520,127 shares of the biopharmaceutical company’s stock after acquiring an additional 49,254 shares during the quarter. ProShare Advisors LLC owned about 0.07% of Celgene Corporation worth $67,549,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the business. BlackRock Inc. lifted its position in Celgene Corporation by 5.7% during the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after acquiring an additional 3,084,227 shares during the period. State Street Corp lifted its position in Celgene Corporation by 2.3% during the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock worth $4,040,668,000 after acquiring an additional 723,844 shares during the period. Jennison Associates LLC lifted its position in Celgene Corporation by 1.2% during the 2nd quarter. Jennison Associates LLC now owns 13,415,734 shares of the biopharmaceutical company’s stock worth $1,742,301,000 after acquiring an additional 156,864 shares during the period. Franklin Resources Inc. lifted its position in Celgene Corporation by 3.3% during the 2nd quarter. Franklin Resources Inc. now owns 11,080,093 shares of the biopharmaceutical company’s stock worth $1,439,025,000 after acquiring an additional 349,974 shares during the period. Finally, Ameriprise Financial Inc. lifted its position in Celgene Corporation by 3.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 9,874,214 shares of the biopharmaceutical company’s stock worth $1,282,369,000 after acquiring an additional 342,580 shares during the period. 79.48% of the stock is owned by institutional investors.

A number of research firms have weighed in on CELG. Cann reaffirmed a “buy” rating and set a $166.00 price objective on shares of Celgene Corporation in a research report on Wednesday. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $175.00 price objective on shares of Celgene Corporation in a research report on Wednesday, August 9th. Vetr raised Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price objective for the company in a research report on Wednesday, August 16th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $162.00 price objective on shares of Celgene Corporation in a research report on Tuesday, September 26th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $160.00 price objective on shares of Celgene Corporation in a research report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $139.57.

TRADEMARK VIOLATION WARNING: This piece was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/proshare-advisors-llc-buys-49254-shares-of-celgene-corporation-celg/1718973.html.

In related news, Director Michael D. Casey sold 9,250 shares of Celgene Corporation stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $139.03, for a total value of $1,286,027.50. Following the transaction, the director now owns 9,250 shares in the company, valued at $1,286,027.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now owns 3,925 shares in the company, valued at approximately $564,768.25. The disclosure for this sale can be found here. Insiders sold 20,227 shares of company stock worth $2,843,956 in the last quarter. 0.95% of the stock is owned by insiders.

Celgene Corporation (NASDAQ:CELG) opened at $104.50 on Wednesday. Celgene Corporation has a fifty-two week low of $94.55 and a fifty-two week high of $147.17. The firm has a market capitalization of $81,211.74, a price-to-earnings ratio of 16.12, a P/E/G ratio of 0.80 and a beta of 1.79. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.

Celgene Corporation (NASDAQ:CELG) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The firm had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter last year, the firm earned $1.58 earnings per share. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. equities analysts forecast that Celgene Corporation will post 6.67 EPS for the current fiscal year.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.